These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. Vogler C, Sands MS, Galvin N, Levy B, Thorpe C, Barker J, Sly WS. J Inherit Metab Dis; 1998 Aug; 21(5):575-86. PubMed ID: 9728337 [Abstract] [Full Text] [Related]
7. Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Poorthuis BJ, Romme AE, Willemsen R, Wagemaker G. Pediatr Res; 1994 Aug; 36(2):187-93. PubMed ID: 7970933 [Abstract] [Full Text] [Related]
8. Vestronidase alfa: Recombinant human β-glucuronidase as an enzyme replacement therapy for MPS VII. Cadaoas J, Boyle G, Jungles S, Cullen S, Vellard M, Grubb JH, Jurecka A, Sly W, Kakkis E. Mol Genet Metab; 2020 May; 130(1):65-76. PubMed ID: 32192868 [Abstract] [Full Text] [Related]
9. A genetically myeloablated MPS VII model detects the expansion and curative properties of as few as 100 enriched murine stem cells. Soper BW, Duffy TM, Vogler CA, Barker JE. Exp Hematol; 1999 Nov; 27(11):1691-704. PubMed ID: 10560917 [Abstract] [Full Text] [Related]
10. Brain transplantation of genetically modified bone marrow stromal cells corrects CNS pathology and cognitive function in MPS VII mice. Sakurai K, Iizuka S, Shen JS, Meng XL, Mori T, Umezawa A, Ohashi T, Eto Y. Gene Ther; 2004 Oct; 11(19):1475-81. PubMed ID: 15295619 [Abstract] [Full Text] [Related]
11. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N, Sly WS, Birkenmeier EH. J Clin Invest; 1994 Jun; 93(6):2324-31. PubMed ID: 8200966 [Abstract] [Full Text] [Related]
12. Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells. Maréchal V, Naffakh N, Danos O, Heard JM. Blood; 1993 Aug 15; 82(4):1358-65. PubMed ID: 8353294 [Abstract] [Full Text] [Related]
13. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Birkenmeier EH, Barker JE, Vogler CA, Kyle JW, Sly WS, Gwynn B, Levy B, Pegors C. Blood; 1991 Dec 01; 78(11):3081-92. PubMed ID: 1954394 [Abstract] [Full Text] [Related]
14. Reduction of lysosomal storage in murine mucopolysaccharidosis type VII by transplantation of normal and genetically modified macrophages. Ohashi T, Yokoo T, Iizuka S, Kobayashi H, Sly WS, Eto Y. Blood; 2000 Jun 01; 95(11):3631-3. PubMed ID: 10828055 [Abstract] [Full Text] [Related]
15. Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses. Soper BW, Pung AW, Vogler CA, Grubb JH, Sly WS, Barker JE. Pediatr Res; 1999 Feb 01; 45(2):180-6. PubMed ID: 10022587 [Abstract] [Full Text] [Related]
16. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Watson GL, Sayles JN, Chen C, Elliger SS, Elliger CA, Raju NR, Kurtzman GJ, Podsakoff GM. Gene Ther; 1998 Dec 01; 5(12):1642-9. PubMed ID: 10023443 [Abstract] [Full Text] [Related]
18. In utero fetal liver cell transplantation without toxic irradiation alleviates lysosomal storage in mice with mucopolysaccharidosis type VII. Barker JE, Deveau S, Lessard M, Hamblen N, Vogler C, Levy B. Blood Cells Mol Dis; 2001 Dec 01; 27(5):861-73. PubMed ID: 11783949 [Abstract] [Full Text] [Related]